Research Analysts Offer Predictions for STOK FY2024 Earnings

Stoke Therapeutics, Inc. (NASDAQ:STOK - Free Report) - Equities researchers at Leerink Partnrs raised their FY2024 EPS estimates for shares of Stoke Therapeutics in a research report issued to clients and investors on Tuesday, November 5th. Leerink Partnrs analyst M. Goodman now anticipates that the company will post earnings of ($2.00) per share for the year, up from their previous estimate of ($2.05). Leerink Partnrs currently has a "Strong-Buy" rating on the stock. The consensus estimate for Stoke Therapeutics' current full-year earnings is ($2.10) per share. Leerink Partnrs also issued estimates for Stoke Therapeutics' Q4 2024 earnings at ($0.50) EPS, FY2025 earnings at ($2.25) EPS, FY2026 earnings at ($2.60) EPS, FY2027 earnings at ($2.75) EPS and FY2028 earnings at ($2.60) EPS.

Other research analysts have also issued research reports about the stock. HC Wainwright reiterated a "buy" rating and set a $35.00 price objective on shares of Stoke Therapeutics in a research note on Wednesday. Leerink Partners started coverage on shares of Stoke Therapeutics in a research note on Monday, October 14th. They set an "outperform" rating and a $18.00 price target on the stock. Wedbush restated an "outperform" rating and set a $17.00 price target on shares of Stoke Therapeutics in a research note on Thursday, July 11th. Finally, Needham & Company LLC restated a "buy" rating and set a $22.00 price target on shares of Stoke Therapeutics in a research note on Wednesday. One analyst has rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, Stoke Therapeutics presently has an average rating of "Buy" and an average price target of $20.83.

Stoke Therapeutics Trading Up 4.6 %

Shares of NASDAQ STOK traded up $0.61 during trading hours on Friday, hitting $13.88. 419,252 shares of the stock were exchanged, compared to its average volume of 759,820. The firm has a fifty day moving average price of $13.24 and a 200-day moving average price of $13.70. Stoke Therapeutics has a 12 month low of $3.77 and a 12 month high of $17.58.

Stoke Therapeutics (NASDAQ:STOK - Get Free Report) last posted its quarterly earnings data on Tuesday, November 5th. The company reported ($0.47) EPS for the quarter, topping the consensus estimate of ($0.52) by $0.05. The firm had revenue of $4.89 million during the quarter, compared to analyst estimates of $3.46 million. Stoke Therapeutics had a negative net margin of 629.90% and a negative return on equity of 54.45%.

Institutional Trading of Stoke Therapeutics

Large investors have recently made changes to their positions in the business. Redmile Group LLC boosted its holdings in Stoke Therapeutics by 93.2% during the first quarter. Redmile Group LLC now owns 5,073,049 shares of the company's stock worth $68,486,000 after buying an additional 2,447,543 shares in the last quarter. Lynx1 Capital Management LP boosted its holdings in Stoke Therapeutics by 40.3% during the second quarter. Lynx1 Capital Management LP now owns 5,185,191 shares of the company's stock worth $70,052,000 after buying an additional 1,488,371 shares in the last quarter. Assenagon Asset Management S.A. purchased a new stake in Stoke Therapeutics during the second quarter worth $19,835,000. Baker BROS. Advisors LP boosted its holdings in Stoke Therapeutics by 65.9% during the first quarter. Baker BROS. Advisors LP now owns 3,368,443 shares of the company's stock worth $45,474,000 after buying an additional 1,338,309 shares in the last quarter. Finally, Healthcare of Ontario Pension Plan Trust Fund boosted its holdings in Stoke Therapeutics by 426.1% during the second quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 1,387,200 shares of the company's stock worth $18,741,000 after buying an additional 1,123,500 shares in the last quarter.

Insider Activity

In other news, major shareholder Skorpios Trust sold 1,937,500 shares of the company's stock in a transaction on Thursday, September 19th. The shares were sold at an average price of $14.05, for a total value of $27,221,875.00. Following the sale, the insider now directly owns 8,906,181 shares of the company's stock, valued at $125,131,843.05. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 11.30% of the company's stock.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.